Aluminum Hydroxide

Overview

Aluminum hydroxide is an orally administered antacid and phosphate binder commonly used in small animal medicine. In dogs and cats, its primary clinical role is the management of hyperphosphatemia associated with chronic kidney disease when dietary phosphorus restriction alone is insufficient.

When administered orally, aluminum hydroxide acts locally within the gastrointestinal tract. It binds dietary phosphorus to form insoluble aluminum phosphate complexes that are excreted in the feces, thereby reducing intestinal phosphorus absorption and lowering serum phosphorus concentrations.

Aluminum hydroxide has also been used occasionally as an oral antacid to increase gastric pH; however, its short duration of action may limit its practicality for routine acid suppression. Because systemic absorption is minimal, its effects are largely confined to the gastrointestinal tract, but prolonged or inappropriate use may lead to electrolyte disturbances or aluminum accumulation.

Indications

In dogs and cats, aluminum hydroxide is used primarily for the management of disorders related to phosphorus balance and, less commonly, for gastric acid neutralization. Its use is generally adjunctive and based on clinical and laboratory findings.

• Hyperphosphatemia associated with chronic kidney disease: Used as an oral phosphate binder in dogs and cats with chronic kidney disease when dietary phosphorus restriction alone fails to maintain serum phosphorus within the desired target range.
• Adjunctive antacid therapy: Occasionally used to reduce gastric acidity in dogs and cats with gastric irritation or ulceration, although its short duration of action may limit clinical usefulness for this indication.

Dosage (Reference)

Dog

In dogs, aluminum hydroxide is used extra-label as an oral phosphate binder for the control of hyperphosphatemia associated with chronic kidney disease. Dosing is individualized based on serum phosphorus concentrations and dietary management.

Cat

In cats, aluminum hydroxide is used extra-label as an oral phosphate binder for the management of hyperphosphatemia secondary to chronic kidney disease. Therapy should be guided by serial monitoring of serum phosphorus levels.

Warnings & Precautions

Aluminum hydroxide should be used with caution in dogs and cats, particularly when administered chronically. Although systemic absorption is poor, prolonged use or inappropriate dosing may lead to electrolyte disturbances or aluminum accumulation.

• Renal disease: Aluminum may accumulate in patients with chronic kidney disease; long-term therapy requires careful monitoring to reduce the risk of aluminum toxicity.
• Constipation risk: Use cautiously in animals prone to constipation, as reduced intestinal motility and firm stools may occur during treatment.
• Gastric emptying: Aluminum-containing antacids may inhibit gastric emptying; use cautiously in patients with suspected gastric outlet obstruction.
• Electrolyte imbalance: Chronic administration, especially in combination with a low-phosphorus diet, may result in hypophosphatemia and associated clinical signs.
• Prolonged use: Long-term therapy may increase the risk of aluminum accumulation and related skeletal or neuromuscular effects.
• Pregnancy and lactation: Safety has not been well established in pregnant or lactating dogs and cats; use only when maternal benefits outweigh potential risks to offspring.

Drug Interactions

Aluminum hydroxide has numerous potential drug interactions, primarily related to changes in gastric pH or binding of concurrently administered oral medications, which can reduce or alter drug absorption. Dose separation is often required to minimize these interactions in dogs and cats.

• Diazepam: Concurrent administration may increase diazepam absorption; monitor for enhanced sedative effects.
• Quinidine: Increased gastric pH may enhance absorption of basic drugs such as quinidine; separate administration by at least 2 hours.
• Vitamin D analogues (e.g., calcitriol, ergocalciferol): May increase aluminum absorption; concurrent use should be avoided due to increased risk of aluminum toxicity.

Aluminum hydroxide can also decrease the oral absorption or clinical effectiveness of the following drugs. To reduce interaction risk, administer these medications at least 2 hours before or after aluminum hydroxide:

• Allopurinol
• Aspirin
• Azole antifungals (e.g., itraconazole, ketoconazole)
• Cefpodoxime
• Corticosteroids (e.g., dexamethasone, prednis(ol)one)
• Digoxin
• Ethambutol
• Fexofenadine
• Fluoroquinolones (e.g., enrofloxacin, marbofloxacin)
• Gabapentin
• H2 antagonists (e.g., famotidine, ranitidine)
• Iron salts (e.g., ferrous sulfate)
• Isoniazid
• Mycophenolate
• Penicillamine
• Phenothiazines (e.g., acepromazine, chlorpromazine)
• Phenytoin
• Sotalol
• Tetracyclines (e.g., doxycycline, minocycline)
• Thyroid hormones

Side Effects & Overdose

Side Effects

Adverse effects associated with aluminum hydroxide in dogs and cats are generally related to gastrointestinal function and disturbances in phosphorus balance, particularly with chronic administration.

• Constipation: The most commonly reported adverse effect in small animals; may be more pronounced with higher doses or prolonged use.
• Hypophosphatemia: Can occur when aluminum hydroxide is used chronically, especially in patients receiving a low-phosphorus diet, potentially leading to weakness or bone-related abnormalities.
• Aluminum toxicity: Rare but possible with long-term use, particularly in dogs with chronic kidney disease; reported cases include neuromuscular signs and hematologic changes.
• Skeletal effects: Osteomalacia may develop secondary to chronic hypophosphatemia or aluminum accumulation with prolonged therapy.

Overdose

Acute toxicity from oral overdose of aluminum hydroxide is unlikely in dogs and cats due to poor systemic absorption. Clinical concerns are more commonly associated with chronic overuse rather than single acute exposures.

• Gastrointestinal effects: Constipation and reduced appetite may occur following acute or chronic excessive dosing.
• Electrolyte disturbances: Overuse may exacerbate hypophosphatemia, particularly in patients on phosphorus-restricted diets.
• Management: Treatment is supportive and based on clinical signs; adjust or discontinue therapy as needed and correct electrolyte abnormalities.
• Consultation: In suspected overdose cases, consultation with a veterinary poison control center is recommended for case-specific guidance.

Key Notes

Practical clinical points to optimize the effective and safe use of aluminum hydroxide in dogs and cats:

• Administration with food: For optimal phosphate binding, aluminum hydroxide should be mixed with meals or given immediately before feeding.
• Formulation preference: Dried aluminum hydroxide gel powder is often preferred because it is tasteless and easier to mix with food compared with liquid suspensions.
• Delayed clinical response: Reduction in serum phosphorus is gradual; dose adjustments should be based on serial laboratory monitoring rather than short-term clinical response.
• Combination binder strategy: In some patients, combining aluminum-based binders with non-aluminum binders may allow lower doses of each and reduce long-term toxicity risk.
• Medication timing: Careful scheduling of oral medications is important to avoid reduced absorption of concurrently administered drugs.
• Long-term management: Aluminum hydroxide is part of a broader chronic kidney disease management plan and should not replace dietary modification or regular monitoring.